Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; and intravenous tramadol for the treatment of post-operative acute pain. It also develops BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc. Show more

1111 Kane Concourse, Bay Harbor Islands, FL, 33154, United States

Biotechnology
Healthcare

Market Cap

1.114M

52 Wk Range

$0.15 - $0.97

Previous Close

$0.29

Open

$0.27

Volume

23,787

Day Range

$0.27 - $0.40

Enterprise Value

-1.741M

Cash

2.855M

Avg Qtr Burn

-854K

Insider Ownership

20.64%

Institutional Own.

7.02%

Qtr Updated

12/31/25